Coriolis Pharma announced that Prof Dr Ernst Wagner has joined its scientific advisory board. Prof Wagner’s distinguished expertise with nucleic acids and gene delivery perfectly fits the services offered by Coriolis Pharma and strengthens Coriolis’ scientific expertise in the field of advanced therapy medicinal products (ATMPs).

“We are pleased to welcome Ernst to our scientific advisory board," said Dr Michael Wiggenhorn, CEO, Coriolis Pharma. “His distinguished expertise about nucleic acids and gene delivery will be of high value to our client projects, particularly in the booming field of advanced therapy medicinal products. Ernst will actively be involved in project discussions and will contribute with his long-year experience to successful project outcomes.”

Prof Wagner is a professor of Pharmaceutical Biotechnology at the Ludwig-Maximilians-Universität (LMU) and the Center of Nanoscience in Munich, Germany. Previously (1991-2001), he was the Director Cancer Vaccines & Gene Therapy at Boehringer Ingelheim in Vienna, Austria, where he supervised the first-in-world polymer-based human gene therapy trial in 1994. Prof. Wagner is an Academician of European Academy of Sciences, a member of the Controlled Release Society (CRS) College of Fellows, a board member of German Society for Gene Therapy, and the Editor-in-Chief of the Journal of Gene Medicine.

Prof Wagner has authored more than 475 publications with almost 45000 citations. His current academic research projects focus on the targeted delivery of nucleic acids (including mRNA) and protein therapeutics.